April M. Breyer

April M. Breyer

Associate, New York

April Breyer practices intellectual property law with an emphasis on complex patent and Hatch-Waxman litigation in the chemical and pharmaceutical arts. She has represented clients at the district court and appellate levels, as well as in three of the first inter partes review proceedings at the U.S. Patent and Trademark Office. April’s practice has focused on damages and commercial success aspects of pharmaceutical and biotechnology litigations, including numerous cases involving oncology treatments. She is actively involved in Fitzpatrick’s biosimilars and biologics practice group, and updates, manages, and provides statistics and other content for the firm's BiologicsHQ microsite.

April has frequently provided pro bono representation including prosecution of various trademarks, analyzing tax provisions, and representation in social security disability proceedings.

Prior to law school, April worked in the Laboratories of Dr. Catherine Verfaillie at the University of Minnesota Stem Cell Institute and the Katholieke Universiteit Leuven Stamcel Instituut, focusing on diabetes and Parkinson’s disease stem cell research.

Case Highlight
April worked with economics experts to develop lost profits and reasonable royalty arguments, aiding in obtaining a favorable settlement for Eli Lilly.
Representative Matters
  • Novartis against Par Pharmaceutical, Roxane Laboratories, and Breckenridge Pharmaceutical in an ANDA patent litigation relating to Novartis’s Zortress® and Afinitor® products.
  • Eli Lilly against Genentech in a patent litigation relating to monoclonal antibodies.
  • Columbia University against Illumina in a patent litigation relating to DNA sequencing products.
  • Warner Chilcott against Mylan, Sandoz, and Impax in an ANDA patent litigation relating to Warner Chilcott’s Doryx® product.